Altimmune (ALT) Stock Forecast & Price Target

Altimmune Inc is positioned positively due to its advanced development of pemvidutide, a dual-action therapy that targets key metabolic dysfunctions, particularly for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver diseases. The company’s recent progress, including a strengthened leadership team and a robust financial foundation with approximately $340 million in pro-forma cash, enhances its ability to execute Phase 3 trials and capitalize on upcoming catalysts, such as the Phase 2 data from the RECLAIM alcohol use disorder trial expected in 3Q26. Additionally, pemvidutide’s unique dual mechanism of action aligns with the growing market emphasis on combination therapies, providing significant potential for clinical success and a widening treatment footprint.

The financial outlook for Altimmune Inc is hindered by significant clinical development risks associated with its lead candidate, pemvidutide, particularly in the context of its uncertain regulatory pathway for treating metabolic dysfunction-associated steatohepatitis (MASH) and other liver diseases. Additionally, potential competition and the lack of established FDA approvals in this space may adversely impact market penetration and revenue forecasts upon any future approval of Altimmune's products. Furthermore, financial analysts express concern regarding the company's need for additional capital, potentially leading to dilution, combined with broader risks such as market conditions, reimbursement challenges, and geopolitical disruptions, which collectively contribute to a negative outlook for the stock.